Case 2 - Five-year old boy, has acquired microcephaly since 12 months of age, absent speech, mental retardation, behavioral problems. Creatine Transport Defect was confirmed with high levels of creatine in urine and hemizygous mutation in the SLC6A8 gene.

Case 3 - Eleven-months old boy, has acquired microcephaly since six months of age, absent speech, hypotonia. He also has α-1-antitrypsin deficiency, increased lactic acid and T4 low. Cerebral magnetic resonance showed global loss of volume of white matter. Muscle biopsy confirmed respiratory chain disorder with complex 2 deficiency - 25%.

Discussion If the patient showed acquired microcephaly and absent speech associated with convulsions and angelman-like features, the most probably diagnosed is Angelman syndrome. The screening for mutation in chromosome 15 diagnosed the syndrome. If the patient has also behavior disturbances with family history of learning disabilities, determination of urine creatine is obligatory to exclude creatine transport defect. If all these tests are negative and the patient has unrelated organs involved, we need to exclude respiratory chain disorder and muscle biopsy is mandatory.

**Conclusion** We emphasize the importance of studying more of cases (Clinic - Genetic) to put an update on the current classification.

The early therapeutic in the management of GD is still advantageous.

**VACTERL ASSOCIATION: A NEW CASE WITH BIOTINIDASE DEFICIENCY AND ANNUlar PANCREAS**

**CANAVAN DISEASE: A CASE REPORT FROM KUWAIT**

**A CHALLENGING CASE OF MAKING CRITICAL CARE DECISION ON THE WITHDRAWAL OF NEONATAL INTENSIVE CARE**

**References**

A Benketira. Pediatric, Military Hospital Regional University of Oran, Oran, Algeria

**Introduction** Gaucher’s disease is the most common of the inherited metabolic disorder known as lipid storage diseases. It is a lysosomal disease, autosomal recessive. It is caused by a deficiency of beta-glucocerebrosidase. The result is a substance called glucocerebroside to build up in cells of the body (Spleen, liver, lungs, bones and sometimes in the brain).

There are three clinical types:

Type 1 95% 1/50000 Subacute Infants/Children Doesn’t involve the brain

Type 2 1% 1/150000 Acute/Deadly Newborn-06 months Severe brain damage

Type 3; 5% 1/100000 Chronic Juvenile/Adult

Brain-Liver-Spleen involvement appear gradually

**Materials and Methods** It’s a baby 13 months old. He had hepatosplenomegaly with cytopenia. He had the neurological signs such pyramidal syndrome with contra version ocular without flutter. The explanation concluded for the GD by the enzymatic dosage.

**Results** After six years of follow up, enzyme replacement therapy (Imiglucerase) has demonstrated its effectiveness as well as biological as clinical. Our observation has been raised the possibility of signs of brain involvement in the type 1. The finding joins a few cases in the literature. This data calls into question the traditional classification cited from above.
agreement with our assessment. Genetic testing was subsequently positive for congenital myotonic dystrophy. Parents finally consented to withdrawal of intensive care at day 64 of life and he died shortly after extubation.

**Conclusion** Critical care decision on withdrawal of intensive care can be a very traumatic experience for families. It is essential to follow the guidance available. As paediatricians we are advocates for the baby but at the same time we have to be empathetic and considerate to the sentiments of the family.

### 535 NECROTIZING ENTEROCOLITIS IN A NEWBORN FOLLOWING INTRAVENOUS IMMUNOGLOBULIN TREATMENT FOR HEMOLYTIC DISEASE

**doi:**10.1136/archdischild-2012-302724.0535

S Kara, H Ulu-Üzkan, Y Yilmaz, A Ankan, U Dilmen, Y Daller Bilge. Ankara Training and Research Hospital, Department of Neonatology, Zekai Tahir Burak Maternity Training Hospital, Department of Neonatology, Ankara Training and Research Hospital, Department of Pediatrics, Ankara, Turkey

ABO iso-immunization is the most frequent hemolytic disease of the newborn. Treatment depends on the total serum bilirubin level, which may increase very rapidly in the first 48 h of life in cases of hemolytic disease of the newborn. Phototherapy and, in severe cases, exchange transfusion are used to prevent hyperbilirubinemia encephalopathy. Intravenous immunoglobulins are used to reduce exchange transfusion. Herein we present a female infant who was admitted to the our NICU because of ABO immune hemolytic disease and after two courses of 1g/kg of IVIG infusion, she developed NEC. Administration of IVIG to newborns with significant hyperbilirubinemia due to ABO hemolytic disease should be cautiously employed and always administered under strict.

### 536 NEONATAL HSV ENCEPHALITIS: CONTROVERSYS OVER DIFFERENT THERAPEUTIC APPROACHES AND THEIR EFFECTS ON NEURO-DEVELOPMENTAL OUTCOMES

**doi:**10.1136/archdischild-2012-302724.0538

A Papandreou, E Lek, A Pahuja, C Ramesh. Paediatrics, West Hertfordshire Hospitals NHS Trust, Watford, UK

**Background and Aims** Neonatal HSV encephalitis is well described and known to cause morbidity. However, there is no consensus regarding its optimal treatment, especially around using suppressive oral therapy after intravenous acyclovir. We aim to discuss treatment controversies and review possible neurodevelopmental outcomes in such cases.

**Methods** We report a case of vertically transmitted neonatal HSV-1 encephalitis and review existing literature on available treatment options (PubMed, EMBASE).

**Results** Our patient became pyrexial (39.0°C) and lethargic on day 7 of life. Investigations revealed a raised CRP (80mg/l) and CSF pleocytosis (WCC–26/mm³, 90% lymphocytes) with normal CSF biochemistry. IV antibiotics were empirically started. After developing encephalopathy and seizures on day 2 of illness, IV acyclovir was added. CSF PCR was positive for HSV-1. EEG showed multifocal irritability/excitability and asymmetrical temporal lobe activities. MRI showed low signal intensity on the ADC map in the medial temporal lobe cortices bilaterally and the right inferior frontal cortex.

21 days of IV acyclovir were completed, following which a repeat CSF sample was negative for HSV-1 PCR. IV antivirals were substituted with oral acyclovir at 1500mg/m²/dose BD for twelve months.

**Conclusions** Literature review reveals controversies in treatment. Repeating HSV PCR at the end of IV treatment is not universally supported. Regarding suppressive oral acyclovir, some studies support doses of 1000–1740mg/m²/dose BD while others favour a 300mg/m²/dose TDS regime. Its optimal duration (6months, 12months or longer) is unclear. Neurodevelopmental outcomes mostly depend on the severity of the initial insult; Evidence that different suppressive treatments influence outcomes is poor.

### 537 AN IMPORTANT CAUSE OF DYSKINESIA

**doi:**10.1136/archdischild-2012-302724.0537

C Peers. Paediatric Neurology, Bristol Children’s Hospital, Bristol, UK

Kernicterus has been referred to a disease of the past. However, we report two cases of kernicterus presenting with a dyskinetic movement disorder. Both cases had neonatal jaundice and were well until the age of 3 years with normal intellect. On examination dystonia, dyskinesia and chorea were seen. Further examination revealed an upgaze palsy and auditory neuropathy.

Kernicterus describes a neurological syndrome resulting from deposition of unconjugated bilirubin in basal ganglia & brainstem nuclei.

With the recent NICE guidance for jaundice therapy these cases highlight the importance of rigorous treatment of hyperbilirubinemia. They also remind us to consider kernicterus as a diagnosis in a child presenting with a movement disorder and normal intellect.

### 538 THE VALUE OF NEAR-INFRARED SPECTROSCOPY (NIRS) IN PERINATAL ASPHYXIA-A CASE REPORT

**doi:**10.1136/archdischild-2012-302724.0538

F Norooz, B Urlesberger, K Klebermans-Schrehof, C Cziba, E Obwegeser, V Giordano, A Berger, M Weninger, M Olschik. Division of Paediatric Neonatology, Intensive Care and Neuropaediatrics, Medical University of Vienna, Vienna; Department of Paediatrics and Adolescent Medicine, Division of Neonatology, Medical University of Graz, Graz, Austria

**Background** Perinatal asphyxia remains a challenging entity. NIRS offers a method to continuously monitor cerebral oxygen saturation.

**Aim** To obtain insight into haemodynamic changes during hypothermia and rewarming in perinatal asphyxia using NIRS.

**Methods** We report of an asphyxiated patient (37+6 weeks’, Apgar 6 and 8 at 1 and 5 minutes, first arterial blood gas pH of 6.67, base deficit –25). NIRS was started during the first hour of life and continued for a total recording time of 125 hours. Simultaneously, we measured brain function using amplitude-integrated electroencephalography (aEEG). On day 7 magnetic resonance imaging (MRI) has been performed. After discharge, the patient was reassessed neurologically.

**Results** The initial cerebral rSO2 was 65%. When cooling was started FTOE was 0.28. At 33.5°C FTOE had decreased to 0.20, cerebral rSO2 increased to 70%. After rewarming cerebral rSO2 was 85%, and FTOE 0.11. Initially, aEEG showed a mixed burst-suppression and discontinuous pattern which improved to a discontinuous pattern only during the first 12 hours. After rewarming aEEG normalized and showed developing sleep-wake cycles. MRI did not show any signs of hypoxic damage. After discharge the patient presented neurodevelopmentally normal.

**Conclusion** After having cooled down the patient, both NIRS and aEEG showed an improvement (increase of rSO2, decrease of FTOE, loss of burst-suppression in aEEG). aEEG displays cerebral function, cerebral NIRS expands information to cerebral oxygen supply and extraction. MRI and neurodevelopmental assessment proved the observed aEEG and NIRS data.

### 539 SEVERE FORM OF CONGENITAL TOXOPLASMOSIS WITH EXTENSIVE CEREBRAL FINDINGS

**doi:**10.1136/archdischild-2012-302724.0539

E A156

Arch Dis Child 2012;97 (Suppl 2):A1–A539

A156

Arch Dis Child 2012;97 (Suppl 2):A1–A539

A156

Arch Dis Child 2012;97 (Suppl 2):A1–A539

A156

Arch Dis Child 2012;97 (Suppl 2):A1–A539

A156